Eli Lilly & Co. v. Medtronic, Inc.
PulseAugur coverage of Eli Lilly & Co. v. Medtronic, Inc. — every cluster mentioning Eli Lilly & Co. v. Medtronic, Inc. across labs, papers, and developer communities, ranked by signal.
1 day(s) with sentiment data
-
Baldness drugs emerge as Wall Street's next major investment opportunity
Wall Street is increasingly focusing on the development of new baldness treatments, viewing them as a significant investment opportunity akin to the recent boom in obesity drugs. Companies like Veradermics, Absci Corp.,…
-
Eli Lilly escalates fight against black market retatrutide
Eli Lilly & Co. is intensifying its efforts to combat the illicit market for retatrutide, an experimental weight-loss drug. The company has filed lawsuits against businesses in the US, particularly in Texas, that are il…
-
Novo Nordisk CEO eyes longevity and aesthetics beyond weight loss drugs
Novo Nordisk's CEO, Mike Doustdar, is exploring new therapeutic areas beyond weight loss and diabetes, including longevity and aesthetic medicine. The company is investigating semaglutide's potential to protect vital or…